Cidara Therapeutics Announces FDA Acceptance for Priority Review of New Drug Application for Rezafungin for the Treatment of Candidemia and Invasive Candidiasis

QIDP designation is reserved for antibacterial and antifungal drug candidates intended to treat serious or life-threatening infections.